Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PharmaCyte Biotech, Inc.
PMCB Shay Capital LLC 1,037,882
5% 1,037,882 increase
(New Position)
Type Company
Symbol Filed By
Symbol Shares Owned
% Owned Shares Vs. Prev Report Filing
2023-01-10
11:57 am
Purchase 13G PharmaCyte Biotech, Inc.
PMCB SABBY MANAGEMENT, LLC 934,456
11% 673,528 increase
(+258.13%)
Wow lmao 15000 shares traded on BZWR today. Winner winner chicken diner The CEO needs to bring out the secret sauce real soon before they shut the trading down back to the pink sheeets. Dilution equals pollution and a new Bently says it all.
Well well well time to put some more secret sauce on this pig of a stock. We might buy some here just for kicks and fun and a profit. If they have any positive news it could double in a day. Have a great day and Rhettt (CEO lol) get back to work your shareholders are waiting for the BS to stop
Time to get back to work 2 months vacation and looking for good things happen . My boy says that PMCB will be going up soon again. The shares that we sold from 2.00 put him in the green big time. Learn how to play in the dirt with the pigs and big money can be made. Good to see KW gone. Have a great day......
# Holding Holder Report Quarter
Shares Held Value Portfolio % Shares Vs.
Prev Report Holding History
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PMCB Ayrton Capital LLC 2022Q3 Stock 1,033,130 $2,480,000 4.3506% 574.68%
(880,000) History
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PMCB Shay Capital LLC 2022Q3 Stock 1,015,666 $2,438,000 0.5264% 3.35%
(32,968) History
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PMCB VANGUARD GROUP INC 2022Q3 Stock 643,174 $1,544,000 0.0000% 0.12%
(800) History
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PMCB K2 PRINCIPAL FUND, L.P. 2022Q3 Stock 611,163 $1,467,000 0.1684% 570.91%
(520,068) History
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PMCB EQUITEC PROPRIETARY MARKETS, LLC 2022Q3 Stock 330,694 $794,000 0.2092% -3.59%
(-12,300) History
(0) History
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PMCB Csenge Advisory Group 2022Q3 Stock 200,104 $480,000 0.0398% 200,104
(New Position) History
PharmaCyte Biotech, Inc.
(cusip = 71715X20)
PMCB GEODE CAPITAL MANAGEMENT, LLC 2022Q3 Stock 175,607 $421,000 0.0001% 0.00%
(0) History
Can't get funnier than this- due to annual cleaning up the office we found 3.2 million shares of BZWR somewhere in the CEO's desk others were in the trunk of the Bentley and some were found just laying around. With the dilution that took place no one at BZWR knows where all the shares are hopefully no more shares show up lol.. Funny stuff and thats why they were a stinky pinky and without a .01 bid they can fall right back to the pinks. Private messages to a single shareholder is not the way a listed stock should do business. Now people can understand why we dumped our shares above .20 when this pos was pumped up. Have a nice day
Im feeling we struck a good deal with Austrianova with our new management wanting to make huge profits and move forward with the PC trial now that KW is out of the way.
Austrianova updates on the GMP aspects of its Cell-in-a-Box® clinical products
by Walter Gunzburg | Nov 29, 2022
‘ ”’ ‘Pathway to a clinical product
All therapeutics go through three phases of clinical trial testing (phase 1, 2 and 3) before market authorization is possible and they are approved for use in patients. Because late stage clinical trials involve more subjects than early stage trials, larger scale production under “Good Manufacturing Production” must be in place – ideally to the scale and parameters required for final market authorization. In contrast, full Chemistry, Manufacturing and Controls information and testing (CMC as it is referred to in the industry) is not required for phase 1 trials. As trials progress to phase 2 and ultimately phase 3, formulation, analytical procedures, and manufacturing processes are refined and improved (see Figure). The extent of CMC, including pharmacological and toxicological studies, thus depends on phase of the IND, the duration of study, the dosage form, etc.
Indeed, it has been reported that roughly one-third of phase 2 candidates that do advance, do not have a scalable and commercially viable manufacturing process in place. This results at best in costly, game-changing delays or at worst in product discontinuation1.
Austrianova’s clinically tested Cell-in-a-Box cell encapsulation technology is the subject of a Drug Master File (DMF) that has been filed with FDA as well as included by PharmaCyte Biotech Inc., in their IND for a Phase 2B clinical trial for pancreatic cancer. Phase 2B studies are generally ‘mini-phase 3’ studies that provide data on efficacy as well as on safety.
The DMF filed with the US FDA by Austrianova contains proprietary, extensive CMC information, commensurate with a late stage clinical product. This information is a resource for ongoing Cell-in-a-Box products in development as well as for future products.
Austrianova also implements quality by design (QbD) in the manufacturing of its encapsulated cell therapies which are classified as advanced therapy medicinal products (ATMP). Both the US FDA and the European Medicines Agency (EMA) introduced QbD in international guidelines more than ten years ago. QbD is a science- and risk-based approach to drug development and manufacturing, and presents an opportunity to add value by building quality into the production process, thereby gaining a business advantage since iterations toward the target product profile are minimized, and the overall risk to the project is reduced. Importantly, for ATMPs such as encapsulated living cells, it is necessary to maintain sterility throughout the manufacturing process which makes the production process more complex when compared to most other products that can be terminally sterilized.
Interesting facts and figures
Some useful facts and figures have recently been reported. According to industry group PhRMA, it takes 10-15 years on average to develop one new medicine from initial discovery through regulatory approval. Tufts Center for the Study of Drug Development (CSDD) also recently reported that clinical research now takes longer than it used to. The costs of developing a new drug has been estimated2 as around $985 million according to a recent paper in JAMA, although this includes all costs from the beginning until getting a treatment on the market.
1. A. Kane, “Phase-Appropriate Formulation and Process Design,” Pharmaceutical Technology 40 (1) 2016. https://www.pharmtech.com/view/phase-appropriate-formulation-and-process-design
2. M. Derep “What’s the average time to bring a drug to market in 2022?” https://lifesciences.n-side.com/blog/what-is-the-average-time-to-bring-a-drug-to-market-in-2022
Taking some profits on some of the .22 shares that we bought. The run from the lows is getting a lil tired for now scaling out of shares almost done. We didnt want to spook the market and we still hold a good size position for now.
lol he will own shares in the next filing he just joined on to PMCB 2 days ago as a director. It funny to see how much money we made here when we bought under 2.00 and it has moved up to 3.00$ . It was a gift knowing what PMCB had 4.00$ in cash per share. I think some saw the million share block trade lol well that was easy money. Good luck have a nice day..........................
BZWR has a low market price because its a POS with "special sauce " the words of the CEO Rhett . I made my guys sell all our holdings once I heard him say that. It was a true pump and dump pitiful how the public gets caught in these pos pumps.
electroCore to Announce Third Quarter 2022 Financial Results on November 3
Will they do a reverse split soon?
electroCore to Announce Third Quarter 2022 Financial Results on November 3
Wow this is very ugly to see. I just read it. Will it become a criminal issue for Li
"On October 13, 2022, Business Warrior Corporation (the “Company”) terminated its employment agreement with Timothy Li for cause as further described below. On October 19, 2022, a majority of the voting power of the Company voted to remove Timothy Li as a director of the Company.
A police report has been filed with the Irvine, California police department.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1830503/000147793222007922/bzwr_8k.htm
PMCB will be just fine as I said we have 4.00$ in cash and smart investors will buy a discounted price like we did 2.00 and under. Now that KW is gone things will get much better
The put options have expired and- funny a 13d was filed as a new 5% holder has arrived. Hedge funds know when to buy a undervalued stock cash per share. I wont say I had anything to do with this lol.
https://www.sec.gov/Archives/edgar/data/1157075/000119380522001435/e621790_sc13g-pharmacyte.htm
Just checking in here- 1 more day left on the put position on PMCB it could get very interesting tomorrow for PMCB. Like I said when we bought a chunk of shares anything under 2.00 was a gift and we all love a low risk buy. PMCB $4.00 plus in cash its a no brainer and now that KW the pos is gone things can really get going to the upside.
Well at least KW made it through his last surgery alive. Lets see what the new board can do to get things done. KW has been lame for the past for months and with what he was going thru its better he stepped down. Im surprised he didnt do it sooner. Good luck and now may the new board get us to cash per share $4.00 at least. Good health to all
We now have a HUGE position in ECOR. We have no Idea who was selling yesterday but we took in a great amount of shares. Got to love these penny stocks. Yesterday buys were a gift. Good luck lets see how high ECOR can go now
I see we are getting close to our buy point.. Like I said .40 or so
Checking in from Spain on PMCB
The data obtained from the pilot study will allow us to finalize the full-scale pig study protocol,
We will present the protocol to the FDA in our planned Type A meeting which will provide us an opportunity to interact with the FDA to receive guidance on this and several other outstanding issues relating to the clinical hold. Subject to any FDA-suggested modifications to the protocol, we are fully prepared to carry on with the full-scale study. We feel that this strategy will provide the greatest likelihood for ultimate success.”
Well it looks like it is the time to buy BZWR. When I sold this above .20 a while back I said I will buy this under .02 again lol well we r back in and lets see what the CEO can do with his secret sauce. there have been many shares for sale and we bot a bunch of them. Have great day and lets see what can happen with this POS.
PHOENIX --(BUSINESS WIRE)-- Business Warrior Corp. (OTCQB: BZWR), the source for success and long-term growth for small businesses, is pleased to announce its successful uplisting from the OTC Pink Market to the OTCQB® Venture Market (the "OTCQB"), effective August 25, 2022 . Business Warrior will continue to trade under the ticker symbol “BZWR.”
Business Warrior invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference .
PHOENIX, AZ / ACCESSWIRE / August 11, 2022 / Business Warrior Corp. (OTC PINK:BZWR), the source for small businesses in America to get more customers, is pleased to announce that it has been invited to present at the Emerging Growth Conference on August 17, 2022 .
The Company hits major milestones in pursuit of uplisting to larger stock exchange
PHOENIX --(BUSINESS WIRE)-- Business Warrior Corp. (OTC: BZWR), the source for small businesses in America to get more customers, today announces the completion of its audited financial statements for fiscal years ending in August 31, 2021 , and August 31, 2020 . The company’s audited financial statements have been posted on OTC Markets.
Business Warrior announces the acquisition of Alchemy Technologies, a global FinTech software as a service (SaaS) company.
Alchemy specializes in creating end-to-end, cloud native lending experiences for other FinTech companies, merchants and banks. The company installs its core solution to a number of different verticals, including:
Personal loans
Point of Sale Financing
Health and Beauty Financing
Construction Loans
Solar and Home Improvement Financing
Small Business Lending
Skillset Financing
Crowdfunding Platforms
A gift from the CELH team thanks again again lol
We are looking to buy this break down to .40.. good luck
looking to buy back those trading shares in PMCB that we sold last week. Im going to have to give him a bonus for the summer trades lol. Have a great day ......................
I think it could be this today- electroCore, a negative ROCE ratio of -0.2% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
Maybe the downgrade :Electrocore (ECOR) Receives a Hold from JMP Securities
Could it of been the earnings for ECOR
Earnings
electroCore (NASDAQ:ECOR) reported its Q2 earnings results on
Earnings
electroCore missed estimated earnings by 14.29%, reporting an EPS of $-0.08 versus an estimate of $-0.07.
Just got a call that ECOR was going down today
Buying many shares under and around 2.00 was a gift for us knowing what PMCB had in cash per share. It was almost as risk free buying xxx
under 3.28 now its 5.50 both of these companies are worth much more than what they went down to. Now that Iroquois is on board I will know much more of what is going on behind closed doors. Carlos the cfo has to go- give him the walking papers hes a book keeper getting way to much in salary and KW will be kept until the takeover by a much bigger fish than Iroquois make a play on PMCB. Have a great day and dont let the airplane noise bother anyone lol
Let the fun begin new high for the yr today and the huge PMCB short didnt even start to cover lol. So glad we bought the discounted shares under $2.00 it was a gift when the stock has $4.00 in cash per share .
PMCB holding up very well
looking very bullish all buys
https://www.barchart.com/stocks/quotes/PMCB/opinion
We bought many shares under and around 2.00$ Ill be happy to sell them back to the gang for a double or triple or even better $$$$. PMCB has 80 million in cash and that alone makes me want to buy the whole company.
Things will get very exciting soon when the good news starts to flow.
From our CEO about the vulture hedge fund : "Iroquois’ Consent Solicitation Is Full of Factual Inaccuracies And Misrepresentations; Their Intentions Should Not Be Trusted
For example, the statement “On August 9, 2021 , Iroquois made its initial investment of $2.5 million in the Company in connection with a private placement offering in which the Company raised nearly $90 million” is misleading, and creates the false impression that Iroquois made a significant and lasting investment of $2.5 million in the Company at a high price per share.
In fact, Iroquois purchased shares and warrants for approximately $300,000 on August 9, 2021 in a $15 million public offering by the Company, and Iroquois then sold all of the purchased shares almost immediately.
On August 19, 2021 , Iroquois purchased shares and warrants for approximately $2.5 million in a $70 million registered direct offering by the Company, and Iroquois then sold all of the purchased shares that very same day. Since that sale of its entire position on August 19, 2021 , Iroquois has continued to purchase and sell the Company’s shares, with an average acquisition price per share which we believe to be similar to the Company’s current trading price on Nasdaq.
Iroquois has opportunistically acquired the Company’s stock at a low price, and seeks your consent to take control of the Company and its cash reserves at your expense and to your detriment.
We have taken some more profits today from our buys at $42 Celh has been a great money maker for us. Thank you John for the great job you have done once again.
Looks like the short position on PMCB is going to be forced to cover very soon. Have a great day...........................
We are taking huge profits today on our calls on AMC holding some calls just in case it goes higher. Thank you AMC you made us a year profit in 2 months lol. $$$$$$ good luck longs
Wow we went big on the June calls huge profits today sold most NIO up 3.00 bang---- and rolled the rest over to cheap out of the money calls... Have a great day..